University of Nebraska

Creighton University

Vireo Systems, Inc.

Heska Corporation

Accuplex, Llc.

Thomas L McDonald

Annika Weber

Geoffrey M Thiele

Dean J Tuma

Kristen Drescher

Michael F Sorrell

Lynell W Klassen

Donald W Miller

Wayne Arthur Jensen

Steven M Tracy

Janet S Andrews

Dennis H Robinson

Samuel C Augustine

Jon C Wagner

Marilynn A Larson

Marilyn A Larson

An antimicrobial composition containing a synergistic combination of an imidazole antifungal agent and activated creatinine is provided, wherein the imidazole antifungal agent represents in the range of about 0.5 mol % to about 30 mol % of the combination of the antifungal agent and the activated creatinine in the composition. Methods for treating bacterial infections, fungal infections, viral infections, and wounds are also provided, as are other methods of use, including methods for disinfecting inert surfaces, methods for preserving food products, and methods for treating plants. In addition, the invention provides a method for enhancing the antifungal effect of an imidazole antifungal agent as well as a method for enhancing the antibacterial effect of activated creatinine. Compositions and methods involving use of activated 2-amino-imidazol-4-one analogs other than activated creatinine are also provided.

Antimicrobial compositions containing a synergistic combination of activated creatinine and an imidazole antifungal agent

The present invention is directed to novel anti-inflammatory immunomodulators including creatinine or a creatinine salt, for example, creatinine hydrochloride. The present invention is also directed to methods for treating inflammation and inducing an immunomodulatory response. In particular, the anti-inflammatory immunomodulators are useful for treating an inflammatory condition or an autoimmune disease.

Compositions and methods for treatment of inflammation

The present invention provides a creatine ester anti-inflammatory compound which may be received by animals and then metabolized into a biologically active form of creatine. The biologically active creatine inhibits the production of chemical mediators, released during an inflammatory response, which are important components in the inflammatory response and the inflammation and pain resulting from physical or chemical trauma to cells and tissue.

Creatine ester anti-inflammatory compounds and formulations

The present invention provides a method for the detection of early renal disease in animals. The method includes the steps of (a) obtaining a sample from an animal to be tested and (b) determining the amount of albumin in the sample. An amount of albumin in the range of from 10 &#x3bc;g/ml to about 300 &#x3bc;g/ml indicates the presence of early renal disease. The present invention also provides antibodies to canine, feline and equine albumin which can be used to detect the presence of early renal disease.

Methods of detecting early renal disease in animals

A rapid and convenient method for detecting inflammatory conditions in breast tissue, such as those associated with mastitis, is described. The method comprises measuring the presence and quantity of Serum Amyloid A (SAA) in milk samples obtained from the breast tissue. The amount of SAA present in the milk is positively correlated with the level of inflammation of the breast tissue, and can localize the inflammation to a particular region of the breast organ, such as a specific quadrant of a cow's udder. Test kits and their use in the method are also described.

Diagnostic assays of secreted biological fluids for detection of infection and inflammatory conditions

A nucleotide sequence encoding human serum amyloid A3 (SAA3), isolated, purified and characterized from human mammary epithelial cells is disclosed. Proteins encoded thereby and methods of use for the same are also disclosed.

Human SAA3 nucleic acid molecule, protein, and methods of use for same

A genomic nucleotide sequence encoding Serum Amyloid A (SAA), isolated and purified from mammalian colostrum, is disclosed. Methods of use for the same in transgenic protocols is also disclosed.

Genomic mammary Amyloid a sequence

A novel protein adduct is disclosed which is associated with the presence of alcohol liver disease. The adduct is a hybrid product of malondialdehyde and acetaldehyde which act synergistically to bind hepatic proteins. The adduct is highly immunogenic and fluorescent. Methods of detection are also disclosed including monoclonal and polyclonal antibodies.

Acetaldehyde and malondialdehyde protein adducts as markers for alcohol liver disease

A novel Serum Amyloid A (SAA), isolated and purified from mammalian colostrum, is disclosed. The SAA has been isolated from colostrum of several mammalian species, including horse, cow and sheep. Nucleic acid molecules encoding the colostrum SAA, and antibodies immunologically specific for the colostrum SAA, are also disclosed.

Growing community of inventors

Omaha, NE, United States of America

Thomas L McDonald